The Cancer Market Outlook to 2011

Innovation is the key driving force in the cancer market creating strong opportunities for biotech and pharma companies to launch new products and benefit from high volume sales and a strong competitive position.

‘The Cancer Market Outlook to 2011’ provides detailed analysis on 9 indications in the cancer market, identifying growth brands, key drug classes and leading companies.

The 6-year epidemiology and product sales forecasts detailed in this report will enable you to evaluate the changes in the competitive positions of leading companies in the cancer market and ensure your R&D pipeline is aligned with future market opportunity to sustain revenue growth.

Key statistics and analysis detailed in this report:

Company analysis and market share of the top 8 players in the cancer market including: Roche, Johnson & Johnson, AstraZeneca, Novartis, Amgen and

Sanofi-Aventis.

Historical analysis of the performance of leading products and pharmaceutical companies over the period 2001-2005.

Epidemiological analysis and forecasts in 9 key indications in the cancer market including: leukaemia, lymphoma, lung, breast, pancreatic, colorectal, and prostate cancer.

Detailed analysis and sales forecasts of high potential products in the pipelines of the major players.

This report will enable you to benchmark the strategies behind the market-leading products of today and identify which products will be best positioned for growth over the period 2006-2011.

Published: October 2006 Format PDF
Table of Contents
Full Table of Contents (PDF)
Price: $2,875.00 / GBP1,437.50